AbbVie’s Epcoritamab shows progression-free survival gain in relapsed/refractory DLBCL trial
Improvements were also seen in complete response rates, duration of response, and time to next treatment
Improvements were also seen in complete response rates, duration of response, and time to next treatment
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Subscribe To Our Newsletter & Stay Updated